Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00770146 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
A Phase 3 study, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT00770146 is a Phase 3 study that has completed, run by Kastle Therapeutics. The registered enrollment target is 158 participants.
The verdict
NCT00770146, a Phase 3 study, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in patients with high cholesterol who are on a maximally tolerated dose of statin and who have a diagnosis that puts them at least at high risk of coronary heart disease (CHD).
Interventions
- DRUG Placebo
- DRUG Mipomersen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00770146
The ClinicalTrials.gov registry entry for NCT00770146 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kastle Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00770146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00770146 about?
NCT00770146 is a clinical study titled "Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients". The purpose of this study is to evaluate the safety and efficacy of dosing with mipomersen for 26 weeks in patients with high cholesterol who are on a maximally tolerated dose of statin and who have a diagnosis that puts them at least at high risk of coronary heart disease (CHD).
What is the current status of trial NCT00770146?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2008-11. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00770146?
The interventions under investigation include: Placebo (DRUG), Mipomersen sodium (DRUG).
Who is sponsoring clinical trial NCT00770146?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.